NASDAQ:ARAVAravive Stock Price, Forecast & News

Aravive's stock was trading at $4.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ARAV shares have increased by 133.3% and is now trading at $11.64. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aravive.

Aravive is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Aravive.

Aravive Inc (NASDAQ:ARAV) issued its earnings results on Wednesday, May, 6th. The company reported ($0.72) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.36) by $0.36. View Aravive's earnings history.

5 brokerages have issued 1 year target prices for Aravive's stock. Their forecasts range from $15.00 to $31.00. On average, they anticipate Aravive's share price to reach $26.00 in the next twelve months. This suggests a possible upside of 123.4% from the stock's current price. View analysts' price targets for Aravive.

Media headlines about ARAV stock have been trending negative this week, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aravive earned a news sentiment score of -2.8 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about Aravive.

Some companies that are related to Aravive include ZIOPHARM Oncology (ZIOP), Frequency Therapeutics (FREQ), Passage Bio (KROS), Homology Medicines (FIXX), VBI Vaccines (VBIV), RAPT Therapeutics (RAPT), Trillium Therapeutics (TRIL), Provention Bio (PRVB), Eagle Pharmaceuticals (EGRX), Neoleukin Therapeutics (NLTX), Cue Biopharma (CUE), Vanda Pharmaceuticals (VNDA), Radius Health (RDUS), AnaptysBio (ANAB) and DiaMedica Therapeutics (DMCAF). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aravive investors own include Flexion Therapeutics (FLXN), Gilead Sciences (GILD), Applied Genetic Technologies (AGTC), Ardelyx (ARDX), Bank of America (BAC), Clovis Oncology (CLVS), Precision BioSciences (DTIL), Galmed Pharmaceuticals (GLMD), Inovio Pharmaceuticals (INO) and Myovant Sciences (MYOV).

Aravive trades on the NASDAQ under the ticker symbol "ARAV."

Shares of ARAV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ARAV stock can currently be purchased for approximately $11.64.

Aravive has a market capitalization of $186.24 million and generates $4.75 million in revenue each year. The company earns $-18,220,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis. Aravive employs 14 workers across the globe.

The official website for Aravive is www.aravive.com.

Aravive's mailing address is River Oaks Tower3730 Kirby Drive Suite 1200, Houston TX, 77098. The company can be reached via phone at 936-355-1910 or via email at [email protected]